Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.23% to $52.76 Tuesday, on what proved to be an all-around poor trading ...

Bristol-Myers Squibb (BMY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners maintained a Hold rating on ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $52.76 which represents a slight increase of $0.64 or 1.23% from the prior close of $52.12. The stock opened at ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec ...

Shares of Bristol Myers Squibb Co. BMY shed 0.76% to $52.40 Thursday, on what proved to be an all-around rough trading ...

Bruce G. Allen Investments LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 22.0% during the ...

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...